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prescription medications. Given the financial burden of using multiple medications, 
and the lower incomes of these patients, cost-saving methods are more frequently 
utilized by these patients.
PIH37
PrelImInary ItalIan arcHIve of eq-5d data on IndIvIduals from tHe 
General PoPulatIon and wItH dIfferent dIsease condItIons
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Objectives: In the last 15 years our research activity collected several HRQoL data, 
through the EQ-5D-3L and other generic (SF-36) or condition-specific question-
naires. The objective was to assess and compare HRQoL among different popula-
tion subgroups. MethOds: We reviewed all the HRQoL studies conducted by our 
research group between 1998 and 2012. We identified several conditions to be com-
pared in terms of VAS score and utility index: these were assessed using the Italian 
social tariffs and then adjusted for age and sex. Results: The archive included 
QoL data from 7,754 subjects (51.5% male), grouped in 29 different subgroups: type 
1 and 2 diabetes mellitus, moderate to severe haemophilia, major depression, 
atopic dermatitis, severe and chronic hand eczema, psoriatic arthritis, schizophre-
nia/schizophrenic disorder, β -thalassemia major, gastroesophageal reflux, abdomi-
nal aortic aneurysm, systemic sclerosis, chronic hepatitis B, chronic hepatitis C, 
hepatitis from other causes, cirrhosis, hepatocellular carcinoma, liver transplant, 
general Italian population aged from 18 to 75 years. Overall, the subjects were aged 
from 14 to 96 years (mean(+SD)= 55.7(+17.1), median= 57.7). The adjusted EQ-5D-
VAS mean+SD ranged from a minimum of 33.9+14.1 in patients with a major 
depression episode, to a maximum of 82.5+12.9 in patients with atopic dermatitis 
8 weeks after flare. The mean+SD VAS was 73.2+11.4 in the general population. The 
adjusted mean+SD utility index ranged from 0.60+0.17 in psoriatic arthritis before 
starting treatment with biological agents, to 0.931+0.09 among chronic hepatitis 
B patients. cOnclusiOns: The many EQ-5D data collected in the last 15 years 
are merged now in a unique archive that can be used to assess and compare the 
burden of disease in terms of HRQoL in different subpopulations. This archive is to 
be considered preliminary and deemed to be integrated with additional data from 
ongoing or future projects, and perhaps with other analogous archives created in 
other contexts and Countires.
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Objectives: A key dimension impacting clinical outcomes in health care evaluation 
is satisfaction (i.e. the level of meeting user’s expectations for the service), which 
impact adherence and persistence. Yet, evidence regarding patient dissatisfaction 
is scarce. Thus, we asked what the level of dissatisfaction is after a health centre 
(HC) visit, and which factors impact the dissatisfaction? MethOds: A prospective 
survey to primary care patients visiting 3 Finnish HCs (Linnainmaa, Omapihlaja, 
Pirkkala) in Pirkanmaa district during 31.1–11.2.2011 was done. No inclusion/exclu-
sion criteria were used. Comprehensive patient-, clinician- and HC-related data was 
collected. The patient’s satisfaction was measured immediately after the visit in the 
form of handling problem during a visit (Likert range 0–10). This was inversed to 
assess the drawback related to the visit (0= full benefit; problem was solved; 10= no 
benefit; full drawback). An explorative statistical analysis was done including mul-
tivariate data mining in order to find the model with the best Akaike information 
criteria. The model aimed to demonstrate the independent factors impacting the 
drawback and control heterogeneity. Results: A total of 90.1% of the full sample 
(n= 647) answered to the drawback question. 40.3% of the patients had problem 
solved during the visit (i.e. reported 0) and just 6.9% of the patients experienced 
drawback exceeding 5. The factors increasing the drawback in the stepwise OLS 
regression model with the +1 ln-transformation for the drawback were longer wait-
ing time, asthma/copd and male sex. The factors decreasing the drawback were 
patient’s higher subjective health status, patient’s higher subjective health status 
in comparison to others of same age/sex, some long-term conditions (rheumatoid 
disease, allergy, hip/knee joint erosion), clinician’s longer experience, clinician in 
specialising education and certain HC. cOnclusiOns: Some 60% of the patients 
experienced that their problem was not fully handled. Multiple factors impact the 
drawback which could be notified in the planning of HC services.
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Objectives: The principal of QALY is sometimes referred to as “A QALY is a QALY 
is a QALY”, which means all QALYs have the same value, while QALYs may not 
fully reflect public preferences. If the use of QALYs in decision making proves 
beneficial but insufficient, what other factors should be taken into consideration 
simultaneously? MethOds: We conducted a face-to-face survey using a discrete 
choice method to measure societal medical care preferences. The profiles of 
assumed patients consisted of the following four factors: (a) age (young or elderly 
patient); (b) objective of care (treatment or prevention); (c) severity of health 
state (severe or mild); and (d) past experience of receiving care (yes or no). These 
Objectives: Of the many routes of drug administration, some are more accept-
able to patients than others; for example when a choice is presented, patients will 
usually prefer an oral over an injectable medication, all else being equal. Patient 
preference may be expressed in terms of health and non-health-related measures, 
which include: health technology-related attributes (including ergonomics, ease of 
use, convenience), behaviour (e.g. needle phobia and patients’ perceptions of treat-
ment), and adverse reactions attributable to the route of administration. Preferences 
may result in process-related (dis)utility, and be revealed as (non)adherence. 
This review aims to examine ambulatory patients’ preferences for subcutane-
ously administered, self-injectable medications, compared with other routes of 
administration for the same medicines. MethOds: Ten electronic databases 
were searched for publications published between 2002 and 2012 using terms 
pertaining to methods of administration, preferences and adherence. Eligibility 
for inclusion was determined through reference to specific criteria by two inde-
pendent reviewers. Results: Of the 1,146 papers screened, 70 met the inclusion 
criteria. Studies focused mainly on methods of administration for insulin and 
treatments of paediatric growth disorders and multiple sclerosis. Pen devices were 
significantly preferred to needle & syringes administration in 11 out of 12 studies 
– particularly with respect to ergonomics, convenience and portability; however, 
preferences between autoinjectors and pen devices were less pronounced. Oral 
administration was preferred to subcutaneous administration in 6 studies (but did 
not reach statistical significance), as was inhaler therapy (favoured significantly 
in 3 out of 4 studies). cOnclusiOns: The review identified a number of studies 
which revealed important differences in patient preference between methods and 
routes of drug delivery. Further evidence is required to support the notion that 
preference translates to better adherence.
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Objectives: Adherence to treatment is an important issue in the management of 
chronic diseases and an indicator of patients’ ability to self-manage their condition. 
Some medical devices have been designed to help support patients’ self-management 
and adherence by including dose-memory and reminder functions. This literature review 
explored the role and impact of these devices on patients’ adherence to treatment, 
confidence and disease self-management. MethOds: A search of Medline, Embase 
and PsycInfo was performed to identify articles published in English from 2003-2013, 
which studied the effect of devices with memory and/or reminder functions on treat-
ment adherence, confidence and self-management. The main attributes of the abstracts 
selected for inclusion and full-text review, were summarized. Results: The database 
searches yielded 940 abstracts. Of the 47 meeting the inclusion criteria, 32 were retained. 
The articles explored the impact of memory and/or reminder devices on treatment 
adherence, device usability and users’ (patients, health care professionals (HCPs) and 
caregivers) relationship and attitudes towards the devices. Devices with memory and/or 
reminder functions were found to improve self-reported and electronically-monitored 
treatment adherence in prophylactic medication use (e.g. contraceptives) and a range 
of chronic diseases including HIV, diabetes and asthma. Memory functions were con-
sidered valuable in disease management by patients and HCPs. Of particular value was 
that memory and/or reminder functions provided dose-history information, enhanced 
patients’ confidence with, and ability to manage their medication and condition, and 
helped reduce forgotten or incorrect medication dosing. cOnclusiOns: The incorpora-
tion of memory functions alone and in combination with reminder features in medical 
devices can improve patient’s adherence, confidence and self-management. This can 
lead to improvements in disease control and clinical outcomes, thereby offering clini-
cal and economic value. This review highlights the importance of conducting further 
qualitative and quantitative research in this area to fully understand the value of these 
types of devices to patients and HCPs.
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Objectives: Compliance with medications among elderly patients is particularly 
important, as the consequences may be quite serious. Results suggest that use of 
three or more medications may put a considerable burden on elderly patients and 
may affect their compliance. This analysis profiles elderly patients across 5EU by 
the number of medications currently used and their compliance related behaviors. 
Combination products were considered as one prescription medication. MethOds: 
Results were taken from the 2011 5EU National Health and Wellness Survey, a 
nationally representative, self-administered survey. Respondents were adults age 
18 and over from France, Germany, Italy, Spain and UK. This analysis focuses on 
adults age > = 65. Physical and mental quality of life was measured using the SF12v2 
scale. Activity impairment was measured using the Work Productivity and Activity 
Impairment scale. Results: Out of the total sample of age > = 65 (n= 10,612), ~37% 
of elderly adults across 5EU currently use four or more prescription (Rx) medica-
tions to treat their conditions, 44% use 1-3 Rx medications, and 18% use no Rx 
medications. Activity impairment is greater among those using 4+ medications 
(38.6 vs. 22.7 vs. 16.0). Emergency room visits and hospitalizations are also higher. 
This group appears to be more proactive in engaging in cost-saving behaviors to 
alleviate some of the treatment costs in the past 6 months (30% vs 24% vs 15%) (e.g., 
asking for generic alternatives (19% vs 16% vs 8%), ever changing prescription to 
another drug (61% vs 51% vs 45%) and switching to a generic version of a prescribed 
drug (35% vs 27% vs 18%). cOnclusiOns: Considerably higher health care costs 
and greater activity impairment can be seen among elderly patients using more 
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tive analysis aims to explore how PRO were used in the French affiliate of 
Roche. MethOds: A total of 89 local studies performed between 2003 and 2013 
were evaluated to determine how PROs were collected and evaluated. Results: 
Forty (45%) out of 89 studies were clinical trials, 44 (49%) were non-interventional 
studies (NIS) and 5 were expanded access program studies. A total of 33 (37%) 
studies used at least one PRO; 13 (39%) were clinical trials and 20 (61%) were NIS. 
There were no PRO in the field of transplantation, 21% of the studies in oncology 
used PRO, 47% in virology, 60% in anemia and 72% in rheumatology. More than 3600 
sites participated in the 33 studies using PRO: 17424 patients were included, 14237 
patients (82%) answered at least one PRO and 12314 (86%) of the questionnaires 
received were considered to be analyzable for statistical analysis (non analyzable 
PROs were usually due to missing data). The median number of questionnaires 
per study was 2, (range 1-6). While most studies in virology and anemia used 1 or 
2 questionnaires per study, rheumatology studies used at least 3 questionnaires 
per study. The median study duration was 12 months, (range 1-60). While 84% of 
PRO were collected at inclusion in the study, 73% of PROs were received after the 
6 month visit, 65% at the 12 month visit and less than 50% after 12 months. Seven 
studies (21%) used PRO as a primary endpoint, and the percentage of patients 
who answered the questionnaire answered was higher (mean 91%) than when 
PRO was a secondary endpoint (mean 79%). cOnclusiOns: Careful consideration 
should be given to number of questionnaires used per study as quality decreases 
as number of evaluations increases.
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Objectives: To confirm the factor structure of the Menopause-Specific Quality of 
Life (MENQOL) questionnaire for a vulvar/vaginal atrophy (VVA) population by apply-
ing confirmatory factor analysis (CFA), and to determine whether improvements in 
health-related quality of life (HRQL) observed in a VVA population with bazedox-
ifene/conjugated estrogens (BZA/CE) relative to placebo can be deemed clinically 
relevant. MethOds: In a randomized control trial, postmenopausal women with 
≥ 1 bothersome moderate-to-severe VVA symptom received BZA 20 mg/CE 0.45 
or 0.625 mg, BZA 20mg or placebo for 12 weeks. HRQL and treatment satisfaction 
were evaluated using the MENQOL questionnaire and the Menopause Symptoms-
Treatment Satisfaction Questionnaire (MS-TSQ), respectively. The structure of the 
MENQOL questionnaire was evaluated using a CFA. Clinically important differences 
(CID) for the MENQOL were determined using a regression model to estimate dif-
ferences in domain and total scores corresponding to one category difference in 
MS-TSQ items, which were used as anchors. Results: The postulated CFA model fit 
the MENQOL data (Bentler’s Comparative Fit Index > 0.9). Treatment with BZA 20 mg/
CE 0.45 and 0.625 mg compared with placebo was associated with statistically sig-
nificant improvements in MENQOL vasomotor and sexual functioning domains, and 
total score (p < 0.001). BZA 20 mg/CE 0.625 mg was also associated with significant 
improvements in physical functioning (p= 0.019). Change from baseline in MENQOL 
vasomotor functioning for BZA 20 mg/CE 0.625 mg over placebo was greater than the 
estimated CID, with BZA 20 mg/CE 0.45 mg approaching CID. Changes in total score 
for BZA 20 mg/CE 0.625 mg compared with placebo also approacöhed CID. Changes 
in MENQOL sexual functioning from baseline over placebo, while statistically signifi-
cant and quite large, were less than the CID estimate. cOnclusiOns: CFA modeling 
provides strong support for the existing factor structure of the MENQOL question-
naire. Improvements in HRQL seen with BZA/CE approached or exceeded CIDs for 
VMS functioning and total score.
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Objectives: Follow up of pelvic floor muscle function after pelvic floor muscle 
training and using cube pessary, paying special attention to the changes in 
the strength of pelvic floor muscle and in the ability to relax. MethOds: To 
determine the degree of the changes in the strength of pelvic floor muscle 
and in the ability to relax, 35 patients had been contacted before provided 
with cube pessaries and pelvic floor muscle training. Thirty out of 35 subjects 
supported our study. Five subjects were excluded due to vaginitis, so finally 30 
survey data were processed. Pelvic floor muscle function measurements were 
performed at the beginning when cube pessaries were given to the subjects 
and later after a 3-week period of usage. Patients were selected with the help of 
the non random sample method. Demographic data and gynecological history 
selection were based on our own general survey questionnaire, while FemiScan 
surface EMG was used to measure pelvic floor muscle strength and the ability to 
relax. Statistical analysis involved t-test or Mann-Whitney U-test, significance 
level was defined at p< 0.05. Results: Although pelvic floor muscle strength 
showed positive changes, statistically significant changes were not detected in 
the surveyed group. In the analysis of survey data of the ability to relax pelvic 
floor muscle statistically significant difference (p= 0,001) could be detected in 
the average results either at the beginning when cube pessaries were given to 
the subjects or after a 3-week period of usage. cOnclusiOns: Cube pessary 
usage and pelvic floor muscle training may have a positive effect on pelvic 
floor muscle function.
factors were orthogonally combined to construct 16 patient profiles. All assumed 
medical care had the same ICER (cost per QALY). Respondents were randomly 
assigned to two of the 16 profiles and asked which one of the patients should 
preferentially receive treatment from a societal point of view, given a limited 
medical resource. Respondents were stratified by age and sex. Results: A total 
of 1091 responses were collected from 50 sites across Japan. The most preferred 
factor was “younger patient (a)”, followed by “treatment (b)” and “severe health 
state (c)”, which had the same degree of preference. No statistical significance 
was found for “no past experience of care (d)”. Public preference for medical care 
for elderly patients increased with increasing age. University-graduated people 
tended to prioritize care for patients who are younger and in severer condi-
tions. cOnclusiOns: Our survey revealed that public medical care preferences 
are influenced by factors such as age, even with the same cost per QALY. Based 
on an economic evaluation, age is an important factor for decision-making that 
reflects societal preferences.
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Objectives: Older people are particularly vulnerable to adverse effects of pre-
scribed drugs. PIP can be defined as the use of medicines with an unfavourable 
risk benefit ratio. There has been little research on the relationship between PIP 
and humanistic outcomes, such as functional impairment. This study aims to 
measure the prevalence of PIP in an older Irish population and to investigate its 
association with IADL impairment. MethOds: A retrospective cohort study of 
2,051 community-dwelling participants in The Irish Longitudinal Study on Ageing 
(TILDA) aged ≥ 65 years with linked medication dispensing history from a national 
pharmacy claims database was carried out. Exposure to PIP in the 12 months prior 
to assessing functional impairment was determined using the Screening Tool for 
Older Persons’ Prescriptions (STOPP), the Beers’ criteria (2012) and Assessing Care 
of Vulnerable Elders (ACOVE) indicators relating to inappropriate medications. 
Logistic regression was used to determine the association between exposure to 
PIP and presence of any IADL impairment, adjusting for age, gender, socioeco-
nomic status, number of repeat drug classes co-morbidity and medication adher-
ence. Results: The overall prevalence of PIP was 66.89% (n= 1,372). Of these 514 
(25.06%) had one instance of PIP, while 858 (41.83%) had two or more. Prevalence 
was highest using the STOPP criteria (57.29%), compared to prevalences of 37.64% 
(Beers’ criteria) and 23.5% (ACOVE indicators. Participants with ≥ 2 PIP indicators 
were significantly more likely to have an IADL impairment (adjusted OR= 1.91; 
95%CI= 1.15-3.18) compared to no PIP. Similar associations were found for the 
individual measures of PIP. Age, number of repeat drug classes and co-morbidity 
were also significantly associated with IADL impairment. cOnclusiOns: PIP in 
the elderly is highly prevalent and exposure to PIP is independently associated 
with increased risk of having IADL impairment. This suggests the importance of 
considering appropriateness when prescribing medicines in order to minimise 
adverse outcomes.
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addInG a remInder sHort messaGe servIce (sms) Before and taBlet 
comPuter durInG clInIc ImProves electronIc PatIent rePorted 
outcome measures (eProms) collectIon
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Objectives: Patient Reported Outcome Measures (PROMs) monitor both symp-
tom progression and treatment effectiveness, and play an increasing role in eve-
ryday clinical practice. Electronic PROMs (ePROMs) enable real-time reporting back 
to the patient and medical team, comparison with similar patient cohorts and 
long-term cost-effective outcome measurement. Concerns have, however, been 
expressed about electronic PROMs collection in the elderly. The primary objective 
of this three-phase pilot study was to measure uptake using a web-based ePROMs 
platform following the introduction of reminder short messaging service (SMS) 
before and Tablet Computer during clinic. MethOds: Eighty-seven consecutive new 
elective orthopaedic patients in a single surgeon’s practice were recruited. Group 
1 (n= 27) received only a reminder letter, Group 2 (n= 34) also received a reminder 
SMS message via mobile or home telephone and Group 3 (n= 26) also had access to 
a Tablet Computer in clinic. Results: Mean age in Group 1 was 55.1 (24-77) years, 
Group 2 was 60.5 (23-85) years and Group 3 was 54.2 (17-77) years (p> 0.05). Overall 
75% patients had Internet access and 33% of Group 1, 50% of Group 2 and 73% 
of Group 3 recorded an ePROMs score (p= 0.03). In Group 2 and 3 26% of patients 
did not remember receiving a SMS message that was delivered. cOnclusiOns: 
Collecting and using PROMs data in everyday clinical practice is challenging. This 
small pilot study shows that adding a reminder SMS before and access to a Tablet 
Computer during clinic improves ePROMs collection onto a clinical outcomes web-
based system. Further process improvements, such as additional staff training and 
telephone call reminders, might further improve uptake and a more comprehensive 
study is planned.
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Past 10 years were evaluated to determIne How PatIent rePorted 
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Objectives: Patient Reported Outcomes (PROs) are increasingly used in clini-
cal studies as well as requested by health authorities (EMA, FDA). This descrip-
